Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Míriam Molina‐Arcas, Julian Downward
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 338-357
Open Access | Times Cited: 46

Showing 26-50 of 46 citing articles:

Novel KRAS Inhibitors for Treating Non-Small-Cell Lung Cancer
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 6, pp. 773-774
Open Access | Times Cited: 1
The Target Therapy Hyperbole: “KRAS (p.G12C)”—The Simplification of a Complex Biological Problem
Massimiliano Chetta, Anna Basile, Marina Tarsitano, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2389-2389
Open Access | Times Cited: 1
The Integrated Stress Response in Pancreatic Development, Tissue Homeostasis, and Cancer
Greg Malnassy, Leah M. Ziolkowski, Kay F. Macleod, et al.
Gastroenterology (2024) Vol. 167, Iss. 7, pp. 1292-1306
Closed Access | Times Cited: 1
Inhibiting the Extracellular Signal-regulated Kinase 1/2 (ERK1/2) Cascade in Cancer and the Heart: for Better or Worse, in Sickness and Health?
Angela Clerk
International Journal of Drug Discovery and Pharmacology (2024), pp. 100006-100006
Open Access | Times Cited: 1
KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination
R. Rosell, Eloísa Jantus‐Lewintre, Peng Cao, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors
Fernando Fernández-García, Ana Fernández‐Rodríguez, Coral Fustero‐Torre, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 36
Closed Access | Times Cited: 1
19Fluorine‐MRI Based Longitudinal Immuno‐Microenvironment‐Monitoring for Pancreatic Cancer
Wilfried Reichardt, Tabea Gewalt, Philipp Hafner, et al.
Journal of Magnetic Resonance Imaging (2024)
Open Access | Times Cited: 1
Unraveling the CDK9/PP2A/ERK Network in Transcriptional Pause Release and Complement Activation in KRAS‐mutant Cancers
Yafang Wang, Lansong Xu, Lijun Ling, et al.
Advanced Science (2024)
Open Access | Times Cited: 1
KRASG12C‐inhibitor‐based combination therapies for pancreatic cancer: insights from drug screening
Constanza Tapia Contreras, Jonas Dominik Falke, Dana‐Magdalena Seifert, et al.
Molecular Oncology (2024)
Open Access | Times Cited: 1
ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal Adenocarcinoma
Dhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Spatial multiplex analysis of lung cancer reveals that regulatory T cells attenuate KRAS-G12C inhibitor–induced immune responses
Megan Cole, Panayiotis Anastasiou, Claudia Lee, et al.
Science Advances (2024) Vol. 10, Iss. 44
Open Access | Times Cited: 1
Untangling sporadic brain arteriovenous malformations: towards targeting the KRAS/MAPK pathway
Rashad Jabarkheel, Lun Li, Maxwell Frankfurter, et al.
Frontiers in Surgery (2024) Vol. 11
Open Access | Times Cited: 1
Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma
Aakash Desai, Alexander Xiao, Daheui Choi, et al.
Cancers (2024) Vol. 16, Iss. 10, pp. 1861-1861
Open Access
Novel KRAS Inhibitors for Treating Non-small Cell Lung Cancer
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 8, pp. 1201-1202
Open Access
Introduction to Neoplasia
Prokopios P. Argyris, Mark C. Herzberg
Elsevier eBooks (2024)
Closed Access
High throughput application of the NanoBiT Biochemical Assay for the discovery of selective inhibitors of the interaction of PI3K-p110α with KRAS
Mohamed Ismail, Gareth M. Davies, Graham Sproat, et al.
SLAS DISCOVERY (2024), pp. 100197-100197
Open Access
Targeting collagen in “armored & cold” tumors: Overcoming barriers to cancer therapy
Shaofei Wang, Jinɡjinɡ Li, Yulei Zhao
Cancer Pathogenesis and Therapy (2024)
Open Access
Role of the TME in immune checkpoint blockade resistance of non-small cell lung cancer
Yuening Dai, Xi Tian, Xuanting Ye, et al.
Cancer Drug Resistance (2024)
Open Access
Targeted KRASG12Vdegradation elicits efficient and durable lung adenocarcinoma regressionin vivo
Alberto J. M. Martín, Inmaculada García-Peréz, Sonia San José, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Intratumor heterogeneity in KRAS signaling shapes treatment resistance
Oleksi Petrenko, Varvara Kirillov, Stephen D’Amico, et al.
iScience (2024) Vol. 28, Iss. 2, pp. 111662-111662
Open Access
Mechanisms of Resistance to KRAS Inhibitors: Cancer Cells' Strategic Use of Normal Cellular Mechanisms to Adapt
Noritaka Tanaka, Hiromichi Ebi
Cancer Science (2024)
Open Access
Previous Page - Page 2

Scroll to top